{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.4","upperLimit":"96.6","value":"84.2"},{"groupId":"OG001","lowerLimit":"23.1","upperLimit":"68.5","value":"45.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"V1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.8","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"4.3","upperLimit":"77.7","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"V2"},{"categories":[{"measurements":[{"comment":"Upper and lower limit of 95% CI was not estimable as the percentage of participants were 0.0 for this specific strain.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0.0"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"V3a"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.2","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"14.7","upperLimit":"94.7","value":"60.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"title":"V3a/b"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.4","upperLimit":"84.3","value":"71.4"},{"groupId":"OG001","lowerLimit":"28.9","upperLimit":"58.9","value":"43.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"No rearrangement"}],"denoms":[{"counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"description":"The Response Genetics, Inc. EML4 ALK reverse transcriptase polymerase chain reaction (RT PCR) gene fusion test was used for the analysis of tissue samples for the ALK gene fusion variants (either no rearrangement, or 1 of 9 results reflecting 8 specific rearrangements \\[V1, V2, V3a, V3b,V3a/b, V4, V5a, V6, V7\\]). Percentage of participants with confirmed CR or PR according to RECIST v1.1 determined by IRR, by type of ALK gene fusion variant were reported in this outcome measure. CR: complete disappearance of all target lesions and non-target disease. All nodes, both target and non-target, must decrease to normal (short axis \\<10 mm). No new lesions and disappearance of all non-target lesions. PR: \\>=30% decrease decrease taking as reference the baseline sum of lesion dimensions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all or target lesions. No clear progression of non-target disease. No new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Crizotinib 250 mg capsule, orally twice daily was administered in treatment cycle of 21 days. Participants could continue crizotinib treatment beyond the time of RECIST v1.1 defined PD, as determined by IRR, at the discretion of the investigator if the participant was perceived to be experiencing clinical benefit.","id":"OG000","title":"Crizotinib"},{"description":"Standard doses of chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) were administered intravenously on Day 1 of each cycle for a maximum of 6 cycles. Pemetrexed 500 mg per meter square (m)\\^2 IV infusion according to standard of care was administered over 10 min; either cisplatin 75 mg/m\\^2 IV infusion was administered approximately 30 min after the end of the pemetrexed infusion or carboplatin was administered at a dose calculated to produce an AUC of 5 or 6 mg\\*min/mL, approximately 30 min after end of pemetrexed infusion.","id":"OG001","title":"Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The ALK variant evaluable population included participants from the FA population who had a result from ALK gene fusion variant testing of either no rearrangement, or 1 of 9 results reflecting 8 specific rearrangements (V1, V2, V3a, V3b, V3a/b, V4, V5a, V6, and V7). Here, n signifies participants who were evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)","title":"Objective Response Rate (ORR) of Anaplastic Lymphoma Kinase (ALK) Variant Groups Based on IRR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}